Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.

British Journal of Clinical Pharmacology

Volumn 35, Issue 1, 1993, Pages 1-7

  Hall, IP ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 5 (4 ACETAMIDOPHENYL) 2(1H) PYRAZINONE; 6 (4 ACETAMIDOPHENYL) 1,2,3,4,4A,10B HEXAHYDRO 8,9 DIMETHOXY 2 METHYLBENZO[C][1,6]NAPHTHYRIDINE; 6 [4 (3 METHYLUREIDO)PHENYL] 3(2H) PYRIDAZINONE; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; BRONCHODILATING AGENT; CILOSTAMIDE; CYCLIC AMP; CYCLIC GMP; DIPYRIDAMOLE; ENOXIMONE; ISOENZYME; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SIGUAZODAN; VINPOCETINE; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULAR BIOLOGY; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; VASODILATATION;

ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; BRONCHODILATOR AGENTS; FIBRINOLYTIC AGENTS; HUMAN; ISOENZYMES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; VASODILATOR AGENTS;

EID: 0027469344     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1993.tb05662.x     Document Type: Article

References (56)

1. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta.
2. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure. A multicenter study.
3. Enoximone and milrinone for severe heart failure.
4. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.
5. A double blind dose‐finding study of rolipram in patients with major depressive disorder.
6. Is phosphodiesterase inhibition a new mechanism of antidepressant action?
7. Adenosine 3′5′‐phosphate in biological materials.
8. Inotropic therapy for heart failure‐an unfulfilled promise.
9. Inhibition of eosinophil respiratory burst activity by type IV but not type III selective cyclic AMP phosphodiesterase inhibitors.
10. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3′5′ monophosphate metabolism, and lipolysis in 3T3‐L1 adipocytes.
11. Bronchodilator potency, effectiveness and time course of inhaled AH 21‐132 in normal human subjects.
12. Could isoenzyme selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?
13. G proteins: transducers of receptor generated signals.
14. Elevation of cyclic AMP in C‐1300 murine neuroblastoma cells by adenosine and related compounds and the antagonism of this response by methylxanthines.
15. Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity.
16. Inhibition of histamine stimulated inositol phospholipid hydrolysis by agents which increase cyclic AMP levels in bovine tracheal smooth muscle.
17. Modulation of carbachol‐induced inositol phosphate formation in bovine tracheal smooth muscle by cyclic AMP phosphodiesterase inhibitors.
18. Effect of isozyme selective phosphodiesterase inhibitors on bovine tracheal smooth muscle tone.
19. Purification of two calcium‐calmodulin dependent forms of cyclic nucleotide phosphodiesterase by using conformation specific monoclonal antibody chromotography.
20. m cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig.
21. Co‐regulation of tracheal tone by cyclic AMP‐ and cyclic GMP‐dependent mechanisms.
22. Cross‐talk between different receptor‐effector systems in the mammallian central nervous system.
23. cGMP phosphodiesterase in rod and cone outer segments of the retina.
24. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose‐response relationships and comparison to nitroprusside.
25. LY 195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum.
26. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides.
27. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain.
28. Intravenous and oral MDL 17043 (a new inotrope‐vasodilator agent) in congestive heart failure: haemodynamic and clinical evaluation in 38 patients.
29. Regulated expression of calmodulin‐dependent cyclic nucleotide phosphodiesterase in the central nervous system.
30. Differential localization of calmodulin‐dependent enzymes in rat brain: evidence for selective expression of cyclic nucleotide phosphodiesterase in specific neurons.
31. Reduction in pulmonary hypertension and in airway resistance by enoximone (MDL 17043) in decompensated COPD.
32. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
33. 3H]‐dipyridamole: a new ligand probe for brain adenosine uptake sites.
34. Molecular basis of the synergistic inhibition of platelet function by nitrovaso‐dilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
35. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.
36. Effect of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst.
37. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes
38. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in bovine tracheal smooth muscle and the ability of isoenzyme inhibitors to relax precontracted preparations.
39. Effect of oral milrinone on mortality in severe chronic heart failure.
40. The role of cyclic AMP in modulating cytotoxic T lymphocytes. II. Sequential changes during culture in responsiveness to cyclic AMP‐active agents.
41. Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated ‘dense vesicle’ and peripheral plasma‐membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat
42. A novel site of action of a high affinity A1 adenosine receptor antagonist.
43. The identification of a new cyclic nucleotide phosphodiesterase activity in bovine and guinea pig cardiac ventricle.
44. High pressure liquid chromotography of cyclic nucleotide phosphodiesterase from purified T‐lymphocytes.
45. Stereospecific binding of the antidepressant rolipram to brain protein structures.
46. 6‐phenyl‐isopropyl‐adenosine.
47. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle.
48. Effects of the cardiotonic/vasodilator agents amrinone and milrinone on phosphodiesterase (PDE) isozymes and contractile force in guinea‐pig cardiac and vascular tissue.
49. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
50. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.
51. Inhibition of the low Km cyclic AMP phosphodiesterase by SK&F 94836: mechanical and biochemical responses.
52. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
53. Neurotropic effects of the optical isomers of the selective adenosine cylic 3′5′ monophosphate phosphodiesterase inhibitor rolipram in rats
54. Induction of a characteristic behavioural syndrome in rats by rolipram and other selective adenosine cyclic 3′5′‐monophosphate (cAMP) phosphodiesterase (PDE) inhibitors.
55. Differential inhibition of human neutrophil functions: role of cyclic AMP‐specific, cyclic GMP‐insensitive phosphodiesterase.